Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ambu ASCHIX:AMBUBC 86 EV-to-EBIT is 28.20 as of Aug. 01, 2026, which is 64% below its 10-year median of 78.27. GuruFocus rates CHIX:AMBUBC with a GF Score™ of 86/100 and a GF Value™ of kr119.75. Among 467 Medical Devices & Instruments companies, Ambu AS ranks worse than 71.31% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ambu AS's Enterprise Value is kr18,836 Mil.
Ambu AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was kr668 Mil. Therefore, Ambu AS's EV-to-EBIT for today is 28.20.
The historical rank and industry rank for Ambu AS's EV-to-EBIT or its related term are showing as below:
CHIX:AMBUBc'
s EV-to-EBIT Range Over the Past 10 Years
Min: 23.79 Med: 78.27 Max: 905.72
Current: 28.2
During the past 13 years, the highest EV-to-EBIT of Ambu AS was 905.72. The lowest was 23.79. And the median was 78.27.
CHIX:AMBUBc's EV-to-EBIT is ranked worse than 71.31% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 18.66
vs CHIX:AMBUBc: 28.20
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Ambu AS's Enterprise Value for the quarter that ended in Mar. 2026 was kr17,999 Mil.
Ambu AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr668 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ambu AS EV-to-EBIT Related Terms
Ambu AS EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Ambu AS's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:AMBUBC vs ABT, SYK, MDT: EV-to-EBIT Comparison
For the Medical Devices subindustry, Ambu AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ambu AS EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ambu AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ambu AS's EV-to-EBIT falls into.
Ambu AS's current Enterprise Value is kr18,836 Mil.
Ambu AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr668 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ambu AS (CHIX:AMBUBC) has a EV-to-EBIT of 28.20 as of Aug. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ambu AS and its competitors. This is 64% below median its historical median of 78.27. Over the past decade, Ambu AS's EV-to-EBIT has ranged from 23.79 to 905.72. According to the industry distribution chart, Ambu AS ranks #333 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 71.3%.
Is Ambu AS's EV-to-EBIT too high?
Ambu AS's current EV-to-EBIT of 28.20 is 64% below median its 10-year median of 78.27. Over the past 10 years, this metric has ranged from a low of 23.79 to a high of 905.72. The Medical Devices & Instruments industry median EV-to-EBIT is 18.66. Ambu AS's value of 28.20 is 51.1% above this industry median. Based on the distribution chart, Ambu AS ranks #333 out of 467 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Ambu AS has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Ambu AS's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ambu AS ranks #333 out of 467 companies for EV-to-EBIT. This places Ambu AS in the lower half of its industry. The industry median EV-to-EBIT is 18.66. Ambu AS's value of 28.20 is 51.1% above this benchmark. Historically, Ambu AS's own EV-to-EBIT has ranged from 23.79 to 905.72 over the past decade. While the company's 10-year median is 78.27 vs. the industry median of 18.66, Ambu AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.66, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ambu AS's current EV-to-EBIT of 28.20 is 51.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ambu AS and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ambu AS's current EV-to-EBIT is 28.20, which is 64% below median its own 10-year median of 78.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambu AS stock overvalued right now?
Ambu AS (CHIX:AMBUBC) has a current EV-to-EBIT of 28.20. The stock's GF Value™ is kr119.75, compared to a current price of kr66.90 — trading 44.1% below its estimated fair value. The current EV-to-EBIT is 28.20, which is 64% below median its 10-year median of 78.27 and 51.1% above the Medical Devices & Instruments industry median of 18.66. Ambu AS's overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Ambu AS (CHIX:AMBUBC), the current EV-to-EBIT is 28.20 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ambu AS (CHIX:AMBUBC) Overvalued in 2026?
Based on GuruFocus' analysis, Ambu AS stock appears to be undervalued.
The current stock price of kr66.90 is trading 44.1% below its estimated GF Value™ of kr119.75.
Key valuation signals for CHIX:AMBUBC:
EV-to-EBIT: 28.20 (64% below median its 10-year median of 78.27)
GF Value™: kr119.75 vs. price of kr66.90 (44.1% below fair value)
Industry Position: 51.1% above the Medical Devices & Instruments median (#333 of 467)
No single metric tells the full story. See the CHIX:AMBUBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ambu AS provides medical technology solutions. The company's business consists of research and development of new solutions, which are then manufactured, marketed, and sold. It operates in two verticals: Endoscopy Solutions and Anesthesia & Patient Monitoring, with the majority of revenue being generated from the Endoscopy Solutions business. Geographical segments include North America, Europe, and the Rest of the World.
86GF Score
Get the complete analysis for CHIX:AMBUBC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMBUBC has been successfully added to your 
